# A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT03893955** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 150 (estimated)

## Conditions studied

- Cancer
- Advanced Solid Tumors
- Triple-Negative Breast Cancer (TNBC)
- Non-small-cell-lung-cancer (NSCLC)
- Metastatic Solid Tumors

## Interventions

- **DRUG:** ABBV-927
- **DRUG:** ABBV-368
- **DRUG:** ABBV-181
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT03893955
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-21
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893955, "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03893955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*